KPMG has announced a partnership with UK company Aiimi to launch a workplace AI platform for data governance across its operations. The collaboration is designed to manage sensitive information and extract insights from the digital estate of KPMG, supporting the firm’s aim to govern data at scale and encourage adoption of AI. The move comes shortly after the Financial Reporting Council’s annual review was published. Aiimi’s platform leverages AI to assist organisations in locating, governing, and unlock ...

Core Viewpoint - KPMG's financial-services practice is under scrutiny due to the U.K. lender bailouts during Brendan Nelson's leadership [1] Group 1 - The scrutiny faced by KPMG is a result of the financial challenges and bailouts experienced by U.K. lenders [1]

Core Insights - Bank of Montreal (BMO) has appointed Tammy Brown to its Board of Directors, enhancing the board's expertise in audit, accounting, finance, and governance [1] - Tammy Brown has a strong background, having served as Deputy Chair of KPMG Canada's Board and as a Partner and National Industry Leader for Industrial Markets at KPMG [1] - BMO Financial Group is the seventh largest bank in North America, with total assets of $1.5 trillion as of October 31, 2025 [2] Company Overview - BMO Financial Group has been serving customers for 200 years, providing a wide range of personal and commercial banking, wealth management, global markets, and investment banking services [2] - The bank serves approximately 13 million customers across Canada, the United States, and select global markets [2] - BMO is committed to driving positive change and fostering a thriving economy, sustainable future, and stronger communities [2]

Key Takeaways VZ faces a saturated market, soft Q3 business demand and rising churn amid fierce competition.VZ posted Q3 revenue declines in its business segment and continues to absorb promo amortization pressure.VZ sees strength in consumer services, broadband additions and new network expansion agreements. Verizon Communications Inc. (VZ) has declined 5.6% in the past six months compared with the Wireless National industry’s decline of 9.4%. The stock has underperformed the Zacks Computer & Technology se ...

Intapp (NasdaqGS:INTA) 2025 Conference December 02, 2025 03:35 PM ET Company ParticipantsKevin D. McVeigh - Managing DirectorJohn Hall - Chairman and CEOThad Jampol - Co-founder and CPOConference Call ParticipantsNone - AnalystKevin D. McVeighGreat. Thank you all in attendance here and for everyone on the webcast. This is truly one of my most favorite firesides because I think John, his team, Thad have done a terrific job, and we were very fortunate to take Intapp public back in 2021. They've just done a re ...

Financial Data and Key Metrics Changes - The company reported a trailing 12-month top-line growth of 12% and a non-GAAP EPS growth of 14%, indicating strong financial performance and operational leverage [26][27]. Business Line Data and Key Metrics Changes - The company launched several new products, including a generative AI product called Dawn and a Compliance Predictor, enhancing its digital health offerings [22][23]. - The company has increased its gross margin by 200-300 basis points year on year, reflecting improved profitability [25]. Market Data and Key Metrics Changes - The company aims to help over 500 million people by 2030 through its healthcare technologies, indicating a strong market focus and growth potential [24]. Company Strategy and Development Direction - The company has restated its 2030 strategy, focusing on product-led, customer-centric, and brand-enhanced growth, with an emphasis on increasing product velocity and profitable growth [25]. - The company is investing 6-7% of its revenues back into technology and 19% into sales and marketing to drive demand generation [27]. Management's Comments on Operating Environment and Future Outlook - Management highlighted the role of artificial intelligence as a tailwind for the company, with ongoing experiments and product launches aimed at improving patient outcomes [21]. - The company has successfully completed acquisitions, including Ectosense and VirtuOx, to enhance its service offerings in sleep apnea testing [28][29]. Other Important Information - The company has increased its share repurchase program from $100 million to $150 million per quarter, with discussions on further increases [28]. Q&A Session Summary Question: How is artificial intelligence a tailwind for the company? - Management discussed the launch of AI-driven products like Dawn and Compliance Predictor, which enhance patient engagement and improve therapy adherence [21][22][23].

RT Bitcoin For Corporations (@BitcoinForCorps)📹WATCH: Risk-Adjusted Bitcoin Treasury StrategyExecutives from @Strive, @arcadiabtc, @KPMG, and @BitMEX show how treasury firms are converting BTC exposure into low-volatility, pension-grade products — building a real on-ramp for risk-averse institutions.📍BFC Symposium Amsterdam ...

Joining me is KPMG's chief economist Diane Swank and CNBC's Steve Leeman. Steve, let me begin with you. Is this a big departure from what we had seen after the last Fed meeting.>> Um, yeah, and by the way, Contessa, unfortunately, you blinked. And, uh, it's an even bigger departure because those probabilities are now down to 41%. Um, and I get that because it's only just been in a little bit that we've had that move.As you saw, uh, the 10-year yield rise higher. uh to around 414 and now the probabilities ha ...

Core Insights - BioStem Technologies, Inc. has filed restated interim financial statements for Q1 2024 through Q2 2025 and annual financial statements for 2023 and 2024, aligning with US GAAP revenue recognition standards [3][12]. Financial Restatement - The restatement is a significant milestone for the company, resulting from a comprehensive review of US GAAP revenue recognition guidance, particularly regarding the distribution agreement with Venture Medical [4][12]. - Bona fide services fees previously recorded as Sales and Marketing expenses will now be classified as contra revenue, reducing gross revenue but not impacting EBITDA, net income, or cash flow [5][12]. - The restated financials will affect percentage-based metrics such as gross margin and EBITDA margin due to the change in revenue reporting [5]. Balance Sheet Adjustments - Amounts owed to Venture Medical related to bona fide services fees will now be netted against Accounts Receivable, effectively offsetting the liabilities between the two companies [6]. Business Outlook - The company maintains that the underlying strength of its business remains unchanged, continuing to deliver clinically validated wound care products [7]. - The independent audit led by KPMG is expected to be completed by the end of Q1 2026, which will support the company's plans to uplist and enhance investor transparency [8][12].

Job Market Overview - The job market is currently challenging for job seekers, with limited hiring announcements and a tough environment for securing positions [2][6]. - Employment is expected to weaken further in the fourth quarter, with minimal gains projected for 2026, indicating a "jobless boom" driven by factors such as federal workforce cuts and immigration restrictions [3]. Seasonal Hiring Trends - Seasonal hiring for the upcoming holiday period is projected to be the smallest since the 2009 recession, with only a few companies committing to increased staffing [6][7]. - Factors affecting seasonal hiring include ongoing tariffs, inflationary pressures, and a reliance on automation and permanent staff rather than large seasonal hires [7]. Opportunities for Job Seekers - Short-term contracts or seasonal positions may provide pathways for frustrated job seekers to transition into full-time roles [4]. - Historical trends show that postings for holiday seasonal contract workers typically increase in September and peak in November, although this year’s hiring pace has been cautious [8].